Clinical validity/utility, change in practice patterns, and economic implications of risk stratifiers to predict outcomes for early-stage breast cancer: a systematic review.
about
Targeted therapies with companion diagnostics in the management of breast cancer: current perspectivesGene expression analysis in RA: towards personalized medicineClinicians' expectations for gene-driven cancer therapyDistribution patterns of 21-gene recurrence score in 980 Chinese estrogen receptor-positive, HER2-negative early breast cancer patients.Predictive and prognostic value of the 21-gene recurrence score in hormone receptor-positive, node-positive breast cancer.The impact of Oncotype DX testing on breast cancer management and chemotherapy prescribing patterns in a tertiary referral centre.E2F4 regulatory program predicts patient survival prognosis in breast cancer.Low Concordance between Gene Expression Signatures in ER Positive HER2 Negative Breast Carcinoma Could Impair Their Clinical Application.Prior knowledge transfer across transcriptional data sets and technologies using compositional statistics yields new mislabelled ovarian cell line.IL-1β induces IL-6 production and increases invasiveness and estrogen-independent growth in a TG2-dependent manner in human breast cancer cellsClinical utility of gene-expression profiling in women with early breast cancer: an overview of systematic reviews.Impact of a genomic classifier of metastatic risk on postoperative treatment recommendations for prostate cancer patients: a report from the DECIDE study group.Breast cancer multigene testing trends and impact on chemotherapy use.Adoption of Gene Expression Profiling for Breast Cancer in US Oncology Practice for Women Younger Than 65 Years.Who gets genomic testing for breast cancer recurrence risk?A mutual activation loop between breast cancer cells and myeloid-derived suppressor cells facilitates spontaneous metastasis through IL-6 trans-signaling in a murine model.The application of Oncotype DX in early-stage lymph-node-positive disease.Recommendations from the EGAPP Working Group: does the use of Oncotype DX tumor gene expression profiling to guide treatment decisions improve outcomes in patients with breast cancer?Implementation of the 21-gene recurrence score test in the United States in 2011.Radiogenomics: A systems biology approach to understanding genetic risk factors for radiotherapy toxicity?Long-term cost-effectiveness of Oncotype DX® versus current clinical practice from a Dutch cost perspective.Interactions between the tumor and the blood systemic response of breast cancer patients.In vivo validation of metastasis-regulating microRNA-766 in human triple-negative breast cancer cells.Re: clinical validity/utility, change in practice patterns, and economic implications of risk stratifiers to predict outcomes for early-stage breast cancer: a systematic review.Addressing overtreatment in breast cancer: The doctors' dilemma.Cost-Effectiveness Analyses of the 21-Gene Assay in Breast Cancer: Systematic Review and Critical Appraisal.Pharmacogenomics in rheumatoid arthritis: how close are we to the clinic?Distribution and Clinical Utility of the 21-gene Recurrence Score in Pure Mucinous Breast Cancer Patients: a case-control study
P2860
Q26768119-9C31A1F3-9FF7-4E57-B2B4-2AE9E3875CEBQ26825706-C16E0F9B-EAF5-465B-ADA4-5B77602CA5C2Q28083844-C50D8758-2CAE-4071-9613-CB0CDED49A0AQ33888929-95BFD94D-24D2-4101-902E-99A41D853928Q34171119-0A69AAE8-6046-4E0F-9F9A-4A277E90B7DAQ34376320-0BA25406-8145-4CD7-B3F5-D58CC6EDC6CAQ35000629-9212B07D-1F3B-4029-90E4-5B3B84D13FC7Q35928728-4A7197F6-D507-4265-BAC7-8DDF5DB8478CQ36063561-EDC058F3-83CD-482E-B1CA-6B207F6C5A44Q36127389-1CD600B4-F655-4B09-9B19-EC75C72AAC0FQ36424052-039E910A-7E6D-44F5-A1BA-0B7CB3414D69Q37038406-14188D53-EB5D-4396-9967-5D2054216DA8Q37083264-36BE3314-0090-4F7C-BDE0-642A17068AD0Q37151779-DEE6EFDC-0130-4D1E-B5E5-C8F162308E3DQ37448876-9D71AE17-4B05-47E8-AB7F-4A848E7E2213Q37691064-485F6DF7-BEDF-4171-95F8-35CB16EE5CD1Q38180001-1ED637A7-93CB-454A-A7AD-0CB9A431A2F3Q38383042-43000FF3-293B-49D2-8E3A-926DB07E7C86Q38409617-09F9F34C-782F-4AAB-BE51-BBA88B29A934Q38761174-FCA42E16-5453-4DE6-88F2-C3DA2AEF7883Q41075349-10BFCC04-61D1-44A3-A688-9DD2BC986F11Q42366134-CF1E643E-EECC-481F-8E6D-4B167F37F7BDQ42379760-EC840994-4630-4F06-8E60-AE3FF0C979FFQ46072841-F5169192-546B-4770-8734-58D3C7255584Q47993032-F5202980-467E-4069-9742-C73E79AF19AFQ52586260-1C6B6E1A-493A-4F7F-A0FE-883020FD7AB7Q52839030-61DFB767-C706-4510-B80B-7A1650560C6BQ57135067-A5F6F1CE-3BFF-448E-9060-F419014AB62A
P2860
Clinical validity/utility, change in practice patterns, and economic implications of risk stratifiers to predict outcomes for early-stage breast cancer: a systematic review.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Clinical validity/utility, cha ...... t cancer: a systematic review.
@en
type
label
Clinical validity/utility, cha ...... t cancer: a systematic review.
@en
prefLabel
Clinical validity/utility, cha ...... t cancer: a systematic review.
@en
P2093
P2860
P356
P1476
Clinical validity/utility, cha ...... t cancer: a systematic review.
@en
P2093
Chien Rebecca
Hialy R Gutierrez
John Hornberger
Michael D Alvarado
Tiffany M Yu
William J Gradishar
P2860
P304
P356
10.1093/JNCI/DJS261
P407
P577
2012-07-05T00:00:00Z